Objective To assess the cost‐effectiveness of a new urinary biomarker‐based risk score
(Select MD x; MD xHealth, Inc., Irvine, CA, USA) to identify patients for transrectal …

Purpose SelectMDx (MDxHealth®) is a panel of urinary biomarkers used in conjunction with
traditional risk factors to individualize risk prediction for clinically significant prostate cancer …

Purpose: We performed a cost-effectiveness analysis using the PHI (Prostate Health Index),
4Kscore®, SelectMDx™ and the EPI (ExoDx™ Prostate [IntelliScore]) in men with elevated …

Study Type–Diagnostic (cost effectiveness) Level of Evidence 2b What's known on the
subject? and What does the study add? The Beckman Coulter prostate health index (phi) …

Objective To assess the economic impact of introducing the prostate health index (phi) for
prostate cancer (PCa) detection. Methods A total of 177 patients who presented in an …

Background. New cancer biomarkers are being discovered at a rapid pace; however, these
tests vary in their predictive performance characteristics, and it is unclear how best to use …

Background Prostate cancer progresses slowly when present in low risk forms but can be
lethal when it progresses to metastatic disease. A non-invasive test that can detect …

Abstract Background Prostate cancer (PCa)(early) detection poses significant challenges,
including unnecessary testing and the risk of potential overdiagnosis. The European …

Although prostate cancer (PCa) is the most commonly diagnosed cancer in men, most
patients do not die from the disease. Prostate specific antigen (PSA), the most widely used …

Background Molecular biomarker tests are developed as diagnostic tools for prostate cancer
(PCa) diagnosis. The SelectMDx (MDxHealth, Nijmegen, The Netherlands) test is a urinary …